The price to be paid for the common stock, $7.13 per share, is equal to the consolidated closing bid price on the Nasdaq global market on the day of pricing, February 13, 2009. The five-year warrants are exercisable at a price of $7.84 per share.
The financing was led by Venrock with participation by Frazier Healthcare Ventures, Domain Associates, Versant Ventures, New Enterprise Associates, Bay City Capital and T Rowe Price Associates.